Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) and Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF)

Status: Recruiting

Eligibility Criteria

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

- at least 40 years old - diagnosis of heart failure with New York Heart Association(NYHA) class II-IV, or hospitalized primarily for heart failure - on a diuretic medication for at least 30 days - left ventricular ejection fraction (LVEF) of at least 40% measured any way in the last 12 months

Exclusion Criteria:

- Myocardial infarction, coronary artery bypass (CABG), stroke or transient ischemic attack (TIA) in the last 90 days - systolic blood pressure (SBP) 160 mmHg or greater if not on treatment with at least 3 blood pressure lowering medications or 180 mmHg or greater irrespective of treatments - additional criteria apply (study staff will review)

Conditions & Interventions

Conditions:
Heart & Vascular
Keywords:
Clinics and Surgery Center (CSC), Heart Failure

More Information

Description: This study is a randomized, double-blind, parallel-group, placebo-controlled, multicenter, event-driven Phase 3 study with independently adjudicated clinical outcome assessments.
Contact(s): Michelle Pitt - henni032@umn.edu
Principal Investigator: Tamas Alexy
IRB
Number: STUDY00010807
System ID: 30295